Positive vasoreactive response in patients with genetically confirmed pulmonary veno-occlusive disease: case report

Pulmonary veno-occlusive disease (PVOD) is verified by identifying typical pathological changes in lungs or mutation in the EIF2AK4 gene. Clinical suspicion is based on combination of specific pulmonary pattern on computed tomography scan, hypoxemia with low diffusing lung capacity (DLCO) and inadequate response to specific therapy of pulmonary arterial hypertension (PAH). The rapid course of PVOD with high mortality determines the importance of early diagnosis and lung transplantation refferal.

We present an unusual clinical case of 40-year-old woman with expected idiopathic PAH and extremely low DLCO with verified EIF2AK4 gene mutation, who demonstrated a positive vasoreactive test (VRT) and clinical response to calcium channel blockers therapy at the onset of the disease. The loss of positive VRT and subsequent PAH specific therapy escalation resulted in PVOD manifestation with severe desaturation, recurrent syncope and pulmonary edema. The combination of low DLCO and inadequate response to PAH therapy in idiopathic PAH patient should be of a paramount awareness of PVOD. Careful PAH therapy escalation with meticulous follow-up, pulmonary multispiral CT and genetic testing could improve early PVOD diagnostics and lung transplantation referral.

1. Holcomb BW Jr, Loyd JE, Ely EW, et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest. 2000 Dec;118(6):1671-9. https://doi.org/10.1378/chest.67.4.487

2. Montani D, Lau EM, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016 May;47(5):1518-34, https://doi.org/10.1183/13993003.00026-2016

3. Montani D, Girerd B, Jaïs X, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med. 2017 Feb;5(2):125-134. https://doi.org/10.1016/S2213-2600(16)30438-6

4. Balko R, Edriss H, Nugent K, et al. Pulmonary veno-occlusive disease: An important consideration in patients with pulmonary hypertension. Respir Med. 2017 Nov;132:203-209. https://doi.org/10.1016/j.rmed.2017.10.015

5. Certain MC, Chaumais MC, Jaïs X, et al. Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest. 2021 Mar;159(3):1197-1207. https://doi.org/10.1016/j.chest.2020.09.238

6. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237

7. Wille KM, Sharma NS, Kulkarni T, et al. Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation. Ann Am Thorac Soc. 2014 Nov;11(9):1411-8. https://doi.org/10.1513/AnnalsATS.201408-354OC

8. Ogawa A, Takahashi Y, Matsubara H. Clinical prediction score for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. J Cardiol. 2018 Sep;72(3):255-260. https://doi.org/10.1016/j.jjcc.2018.02.009

9. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354-62. https://doi.org/10.1378/chest.11-0676

10. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the reveal risk score calculator 2.0 and comparison with esc/ers-based risk assessment strategies. Chest. 2019;156(2):323-337. https://doi.org/10.1016/j.chest.2019.02.004

11. Koyama M, Yano T, Kikuchi K, et al. Favorable response to an endothelin receptor antagonist in mitomycin-induced pulmonary veno-occlusive disease with pulmonary capillary hemangiomatosis. Int J Cardiol. 2016 Jun 1;212:245-7. https://doi.org/10.1016/j.ijcard.2016.03.118

12. Hoeper MM, Eschenbruch C, Zink-Wohlfart C, et al. Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease. Respir Med. 1999 Jan;93(1):62-4. https://doi.org/10.1016/s0954-6111(99)90079-3

13. Barreto AC, Franchi SM, Castro CR, et al. One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. Braz J Med Biol Res. 2005 Feb;38(2):185-95. https://doi.org/10.1590/s0100-879x2005000200006